Skip to content

A cross-sectional study of gut microbiota

A cross-sectional study of gut microbiota - A cross-sectional study of gut microbiota

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000058720
Enrollment
250
Registered
2025-08-07
Start date
2025-08-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteer

Interventions

None listed

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects who are voluntarily giving written informed consent. 2) Healthy volunteers aged between 50 and 79. 3) Subjects whose BMI is below 30.

Exclusion criteria

Exclusion criteria: (1) Subjects who cause allergic symptoms in foods and medicines. (2) Subjects who contract or are under treatment for diseases. (3) Subjects with systolic blood pressure of 140 mmHg or more or diastolic blood pressure of 90 mmHg or more at screening test. (4) Alcoholic drinkers (more than 40 grams of pure alcohol per day). (5) Subjects whose dietary patterns are highly irregular and may interfere with the study outcomes. (6) Subjects who can't stop using, medicin, supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) during test periods. (7) Subjects with exercise habits that may influence the outcomes of the study. (8) Subjects who are judged unsuitable for the current study by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
Evaluation of muscle parameters, gut microbiota, and background information of the subject

Countries

Japan

Contacts

Public ContactHiroki Noguchi

Otsuka Pharmaceutical Co., Ltd. Nutraceuticals Research Institute (Otsu research site)

Noguchi.Hiroki@otsuka.jp077-519-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026